Key Inclusion Criteria (Phase 1a and Phase 1b, all Cohorts):

          1. Available fresh or archived tumor tissue.

          2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.

          3. Adequate coagulation function.

          4. Adequate hepatic function.

          5. Adequate hematologic status.

          6. Adequate renal function.

          7. Recovery from non-hematopoietic toxicities of previous anticancer drugs or
             radiotherapy or previous surgeries to ≤Grade 1 (or to baseline grade if condition was
             pre-existing).

        Key Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory lymphoma
        (Hodgkin or non-Hodgkin).

        Key Inclusion Criteria (Phase 1b Cohort A): Histologically confirmed, newly diagnosed
        TP53-mutated Acute Myeloid Leukemia (AML).

        Key Inclusion Criteria (Phase 1b Cohort B): Histologically confirmed, newly diagnosed
        TP53-wildtype AML, elderly or unfit for more aggressive treatment.

        Inclusion Criteria (Phase 1b Cohort C): Histologically documented relapsed/refractory
        Multiple Myeloma (MM).

        Key Exclusion Criteria (Phase 1a and Phase 1b, all Cohorts):

          1. Known, current central nervous system disease involvement.

          2. Use of any investigational agent or any anticancer drug within 14 days before planned
             start of study treatment (within 4 weeks for antibody-based therapies and within 8
             weeks for cell-based therapies).

          3. Subjects who have undergone radiation therapy within 14 days of study treatment
             administration.

          4. Hematopoietic stem cell transplant within 90 days before the planned start of study
             treatment or subjects with active graft-vs-host disease, with the exception of Grade 1
             skin involvement.

          5. Major surgery within 30 days before planned start of study treatment.